Analyst firms · BofA Securities · MRNA
BofA Securities MRNA price target and rating history
Moderna Inc. (MRNA) · Health Care
BofA Securities rates Moderna Inc. (MRNA) Neutral with a $41 price target, as of its latest action on Aug 19, 2026. It has published 3 rating actions on MRNA since January 2022, including 2 upgrades and 0 downgrades. Across 6 firms with a MRNA price target in the last 12 months, the median target is $57.
- Current rating
- Neutral
- Price target
- $41
- Median target, all firms
- $57
- Actions on MRNA
- 3
BofA Securities price target on MRNA
Every BofA Securities rating on MRNA
- Aug 19, 2026
- Dec 10, 2024
- Jan 21, 2022
How other firms rate MRNA
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| William Blair | Mkt Perform | Oct 27, 2026 | |
| Citigroup | Sell | $80 | Sep 30, 2026 |
| Rothschild & Co Redburn | Sell | $81 | Sep 3, 2026 |
| Argus Research | Buy | $180 | Aug 28, 2026 |
| Wolfe Research | Peer Perform | Aug 25, 2026 | |
| BofA Securities | Neutral | Aug 19, 2026 | |
| Barclays | Equal Weight | $25 | Jan 28, 2026 |
| UBS | Neutral | $34 | Jan 7, 2026 |
| Jefferies | Hold | $30 | Dec 12, 2025 |
Questions about BofA Securities and MRNA
- What is BofA Securities's price target for MRNA?
- BofA Securities's latest stated price target for Moderna Inc. (MRNA) is $41, from its action on Dec 10, 2024.
- What is BofA Securities's rating on MRNA?
- BofA Securities rates MRNA Neutral, a neutral rating, as of Aug 19, 2026.
- When did BofA Securities last change its view on MRNA?
- On Aug 19, 2026, BofA Securities upgrades to Neutral from Underperform.
- How does BofA Securities's MRNA target compare with other analysts?
- Across 6 firms with a MRNA price target in the last 12 months, the median target is $57.
More MRNA rating histories
- William Blair3
- Argus Research3
- Wolfe Research3
- Barclays4
- UBS3
- Jefferies5
- HSBC5
- Oppenheimer3
- Deutsche Bank7
- TD Cowen4
- Leerink Partners5
- Morgan Stanley5
- Piper Sandler3
All BofA Securities ratingsMRNA news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.